Marker Therapeutics Ownership
| MRKR Stock | USD 3.10 0.15 5.08% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 8.9 M | Current Value 8.9 M | Avarage Shares Outstanding 1.9 M | Quarterly Volatility 3.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Marker |
Marker Stock Ownership Analysis
About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Marker Therapeutics was now reported as 1.58. The company recorded a loss per share of 1.07. Marker Therapeutics last dividend was issued on the 16th of September 2016. The entity had 1:10 split on the 27th of January 2023. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To find out more about Marker Therapeutics contact Peter MBA at 713 400 6400 or learn more at https://markertherapeutics.com.Besides selling stocks to institutional investors, Marker Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Marker Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Marker Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Marker Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Marker Therapeutics Insider Trades History
About 12.0% of Marker Therapeutics are currently held by insiders. Unlike Marker Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Marker Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Marker Therapeutics' insider trades
Marker Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Marker Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marker Therapeutics backward and forwards among themselves. Marker Therapeutics' institutional investor refers to the entity that pools money to purchase Marker Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 11 K | Advisor Group Holdings, Inc. | 2024-06-30 | 7.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.8 K | Bank Of America Corp | 2024-06-30 | 2.6 K | Tower Research Capital Llc | 2024-06-30 | 1.9 K | Riggs Asset Management Co Inc | 2024-09-30 | 1.2 K | U.s. Bancorp | 2024-06-30 | 839 | Wells Fargo & Co | 2024-06-30 | 232 | Group One Trading, Lp | 2024-06-30 | 178 | Nea Management Company, Llc | 2024-06-30 | 1.1 M | Aisling Capital Management Lp | 2024-09-30 | 314.3 K |
Marker Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marker Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marker Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marker Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marker Therapeutics Outstanding Bonds
Marker Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Marker Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Marker bonds can be classified according to their maturity, which is the date when Marker Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MARKEL P 5 Corp BondUS570535AQ71 | View | |
| MARKEL P 35 Corp BondUS570535AR54 | View | |
| MARKEL P 43 Corp BondUS570535AS38 | View | |
| US570535AV66 Corp BondUS570535AV66 | View | |
| MKL 6 Corp BondUS570535AW40 | View | |
| US570535AT11 Corp BondUS570535AT11 | View |
Marker Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 17th of May 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Pair Trading with Marker Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Marker Stock
| 0.57 | MTEM | Molecular Templates | PairCorr |
| 0.47 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.47 | ME | 23Andme Holding | PairCorr |
| 0.45 | TPST | Tempest Therapeutics | PairCorr |
| 0.43 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.
The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.